Diagnostic value of plasma asymmetric and symmetric dimethylarginine levels in liver transplant recipients

Polskie Archiwum Medycyny Wewnetrznej

Volumn 122, Issue 7-8, 2012, Pages 367-373

  Wnuk, Zuzanna ^a   Kokot, Franciszek ^b   Kunsdorf Wnuk, Anna ^c  

^a St Barbara Hospital   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c Miel cki Hospital   (Poland)

Author keywords

Asymmetric dimethylarginine; Liver cirrhosis; Liver failure; Liver transplantation; Symmetric dimethylarginine

Indexed keywords

6 N,N' DIMETHYLARGININE; ALANINE AMINOTRANSFERASE; ALBUMIN; ARGININE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ELECTROLYTE; GAMMA GLUTAMYLTRANSFERASE; N(G),N(G) DIMETHYLARGININE; SODIUM;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIAGNOSTIC VALUE; ELECTROLYTE BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; SODIUM BLOOD LEVEL;

EID: 84866054670     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1355     Document Type: Article

References (33)

1. Krawczyk M, Zaborowski P, Pa̧czek L. [Liver transplantation]. In: Rowiński W, Wałaszewski J, Pa̧czek L (eds). [Clinical transplantology]. Warszawa, Poland: PZWL; 2004: 348-383. Polish.
2. Inglott FS, Mathie RT. Nitric oxide and hepatic ischemia-reperfusion injury. Hepatogastroenterology. 2000; 47: 1722-1725.
3. Böger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr. 2004; 134 (10 Suppl): 2842S-2847S.
4. Morimoto H, Nakao K, Fukuoka K, et al. Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients. Nephrol Dial Transplant. 2005; 20: 2775-2782.
5. Bełtowski J, Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol Rep. 2006; 58: 159-178.
6. Piatti PM, Fragasso G, Monti LD, et al. Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels. Circulation. 2003; 107: 429-436.
7. Schulze F, Maas R, Freese R, et al. Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest. 2005; 35: 622-626.
8. Böger RH, Ron ES. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev. 2005; 10: 14-23.
9. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol. 2004; 24: 1023-1030.
10. Dooley A, Gao B, Bradley N, et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford). 2006; 45: 676-684.
11. Usui M, Matsuoka H, Miyazaki H, et al. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci. 1998; 62: 2425-2430.
12. Kielstein JT, Bode-Böger SM, Hesse G, et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscl Thromb Vasc Biol. 2005; 25: 1414-1418.
13. Böger RH, Bode-Böger SM, Thiele W, et al. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol. 1998; 32: 1336-1344.
14. Laleman W, Omasta A, Van de Casteele M, et al. A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology. 2005; 42: 1382-1390.
15. Krzyzanowska K, Mittermayer F, Schnack C, et al. Circulating ADMA concentrations are elevated in hypopituitary adults with and without growth hormone deficiency. Eur J Clin Invest. 2005; 35: 208-213.
16. Jung CS, Oldfield EH, Harvey-White J, et al. Association of an endogenous inhibitor of nitric oxide synthase with cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg. 2007; 107: 945-950.
17. Mookerjee RP, Dalton RN, Davies NA, et al. Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure. Liver Transpl. 2007; 13: 400-405.
18. Chabrier PE, Demerlé-Pallardy C, Auguet M. Nitric oxide synthases: targets for therapeutic strategies in neurological diseases. Cell Mol Life Sci. 1999; 55: 1029-1035.
19. Sugai M, Ohta A, Ogata Y, et al. Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients. Endocr J. 2007; 54: 303-309.
20. Anderstam B, Katzarski K, Bergström J. Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. Am Soc Nephrol. 1997; 8: 1437-1442.
21. Vishwanathan K, Tackett RL, Stewart JT, Bartlett MG. Determination of arginine and methylated arginines in human plasma by liquid chromatography- tandem mass spectrometry. J Chromatogr B Biomed Sci Appl. 2000; 748: 157-166.
22. Becker T, Mevius I, de Vries DK, et al. The L-arginine/NO pathway in end-stage liver disease and during orthotopic liver and kidney transplantation: biological and analytical ramifications. Nitric Oxide. 2009; 20: 61-67.
23. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2010; 51: 576-584.
24. Montoliu S, Ballesté B, Planas R, et al. Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites. Clin Gastroenterol Hepatol. 2010; 8: 616-622.
25. Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009; 49: 2087-2107.
26. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol. 2010; 52: 605-613.
27. Biancofiore G, Davis CL. Renal dysfunction in the perioperative liver transplant period. Curr Opin Organ Transplant. 2008; 13: 291-297.
28. Gonwa TA, Jennings L, Mai ML, et al. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl. 2004; 10: 301-309.
29. Jorkasky DK, Audet P, Shusterman N, et al. Fenoldopam reverses cyclosporine-induced renal vasoconstriction in kidney transplant recipients. Am J Kidney Dis. 1992; 19: 567-572.
30. Planinsic RM, Lebowitz JJ. Renal failure in end-stage liver disease and liver transplantation. Int Anesthesiol Clin. 2006; 44: 35-49.
31. Tai E, Chapman JR. The KDIGO review of the care of renal transplant recipient. Pol Arch Med Wew. 2010; 120: 237-242.
32. Kielstein JT, Veldink H, Martens-Lobenhoffer J, et al. SDMA is an early marker of change in GFR after living-related kidney donation. Nephrol Dial Transplant. 2010; 26: 324-328.
33. Hyla-Klekot L, Kokot F. [Biomarkers of kidney injury]. Post N Med. 2009; 22: 28-33. Polish.